Intellia Therapeutics, Inc. (NTLA)
Automate Your Wheel Strategy on NTLA
With Tiblio's Option Bot, you can configure your own wheel strategy including NTLA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NTLA
- Rev/Share 0.5096
- Book/Share 6.8952
- PB 3.7548
- Debt/Equity 0.1434
- CurrentRatio 5.1932
- ROIC -0.6166
- MktCap 2779210879.0
- FreeCF/Share -4.0664
- PFCF -6.5886
- PE -5.5928
- Debt/Assets 0.1141
- DivYield 0
- ROE -0.5769
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NTLA | Citizens JMP | Market Perform | Mkt Outperform | -- | $33 | Oct. 6, 2025 |
| Upgrade | NTLA | Wolfe Research | Peer Perform | Outperform | -- | $21 | April 21, 2025 |
| Initiation | NTLA | H.C. Wainwright | -- | Buy | -- | $30 | March 5, 2025 |
| Downgrade | NTLA | Goldman | Neutral | Sell | -- | $9 | Feb. 28, 2025 |
| Downgrade | NTLA | JP Morgan | Overweight | Neutral | $45 | $13 | Feb. 28, 2025 |
| Downgrade | NTLA | Morgan Stanley | Overweight | Equal Weight | $56 | $11 | Jan. 27, 2025 |
News
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
Read More
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 63.7% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Read More
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Results were presented in an oral session on Thursday, September 25 at the 5th International ATTR Amyloidosis Annual Meeting for Patients and Doctors in Baveno, Italy. The results were simultaneously published in the New England Journal of Medicine, and the presentation will be available on the Scientific Publications & …
Read More
Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis
Published: September 19, 2025 by: Seeking Alpha
Sentiment: Positive
News shared this week that Intellia Therapeutics, Inc.'s pivotal study of candidate lonvo-z is fully enrolled has been greeted warmly by the market, with good reason. NTLA stock remains a compelling Buy, driven by strong progress in its late-stage gene editing therapies for HAE and ATTR-CM. NTLA's lead candidate, lonvo-z, has completed Phase 3 enrollment for HAE, offering a one-time infusion advantage over competitors and strong regulatory support.
Read More
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
Read More
Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Read More
Why big players are pouring millions in THIS biotech stock
Published: September 01, 2025 by: Invezz
Sentiment: Positive
Intellia Therapeutics (NASDAQ: NTLA) has been getting a lot of buzz lately among investors who follow the biotech space. The company uses CRISPR gene editing technology to develop treatments, and while their stock has been all over the place historically, something's changed in 2025 that has people taking notice.
Read More
Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
Published: August 15, 2025 by: Seeking Alpha
Sentiment: Positive
Intellia Therapeutics, Inc.'s lead gene-editing therapies, Lonvo-z and Nex-z, show best-in-class potential with 'one and done' treatment and strong early efficacy and safety data. Recent safety concerns in ATTR-CM seemed to be resolved quickly, and robust patient demand in pivotal trials support confidence in upcoming Phase 3 data and commercial launches. Cash runway extends into late 2026, but pivotal 2025 catalysts and potential blockbuster approval in multi-billion dollar markets could drive significant upside.
Read More
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Read More
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $1.31 per share a year ago.
Read More
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
An updated edition of the June 27, 2025, article.
Read More
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
Read More
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
Read More
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 398.3% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.
Read More
Analysts Think These Stocks Could More Than Double in Value
Published: May 23, 2025 by: MarketBeat
Sentiment: Negative
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.
Read More
INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Intellia Therapeutics, Inc. (NASDAQ:NTLA) on behalf of long-term stockholders following a class action complaint that was filed against Intellia on February 11, 2025 with a Class Period from July 30, 2024 to January 8, 2025. Our investigation concerns whether the board of directors of Intellia have breached their fiduciary duties to the company.
Read More
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Read More
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) BofA Securities 2025 Healthcare Conference May 13, 2025 7:20 PM ET Company Participants Ed Dulac - CFO Conference Call Participants Alec Stranahan - BofA Securities Alec Stranahan Hello, everyone. Thanks for joining the session with Intellia Therapeutics on day 1 of the 2025 Bank of America Healthcare Conference.
Read More
Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Investors who've been looking for problems at Intellia Therapeutics have, during the past year, had an easy time finding them. A tendency to misinterpret helped. Investors complained about test results that were fine with medical experts and the FDA. The Street hated when NTLA dropped a lesser program and laid off some staff members. On 5/8/25, the Company reported further progress with two treatments that are now ensconced in Phase III of testing—a level only a third of new drugs reach.
Read More
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates.
Read More
Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q1 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Brittany Chaves - Senior Manager of Investor Relations John Leonard - President and Chief Executive Officer David Lebwohl - Chief Medical Officer Ed Dulac - Executive Vice President and Chief Financial Officer Birgit Schultes - Executive Vice President and Chief Scientific Officer Conference Call Participants Gena Wang - Barclays Kostas Biliouris - BMO Capital Markets Luca Issi - RBC Maury Raycroft - Jefferies Mitchell Kapoor - H. C. Wainwright Jay Olson - Oppenheimer Rick Bienkowski - Cantor Fitzgerald Yanan Zhu - Wells …
Read More
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.06 per share a year ago.
Read More
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, NTLA broke out above the 50-day moving average, suggesting a short-term bullish trend.
Read More
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET.
Read More
About Intellia Therapeutics, Inc. (NTLA)
- IPO Date 2016-05-06
- Website https://www.intelliatx.com
- Industry Biotechnology
- CEO John M. Leonard
- Employees 403